Research programme: p38 MAP kinase inhibitors - ArQule

Drug Profile

Research programme: p38 MAP kinase inhibitors - ArQule

Alternative Names: ARQ-101

Latest Information Update: 26 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArQule; SignalGene [CEASED]
  • Class Oxazoles; Thiazoles
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 23 Sep 2005 Compounds arising from this programme are available for out-licensing (
  • 23 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th ACS-2005) have been added to the Rheumatic Disease pharmacodynamics section
  • 01 Sep 2005 ARQ 101 from this programme is still in active development - BIO-2005 Annual International Convention (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top